p53

Model validation / held-out benchmark

20 published formulations · never used to fit the models

← Designer

p53-LNP Designer model validation against held-out literature formulations

Parity plot — Encapsulation

01
H01 DLin-MC3-DMA: observed 94.0%, predicted 97.0%H02 DLin-MC3-DMA: observed 91.0%, predicted 97.0%H03 ALC-0315: observed 90.0%, predicted 97.0%H04 SM-102: observed 93.0%, predicted 97.0%H05 C12-200: observed 87.0%, predicted 97.0%H06 DLin-KC2-DMA: observed 89.0%, predicted 97.0%H07 306Oi10: observed 85.0%, predicted 97.0%H08 Lipid 5: observed 95.0%, predicted 97.0%H09 cKK-E12: observed 86.0%, predicted 97.0%H10 9A1P9: observed 84.0%, predicted 97.0%H11 BAMEA-O16B: observed 88.0%, predicted 97.0%H12 TT3 (FTT5): observed 78.0%, predicted 97.0%H13 L319: observed 92.0%, predicted 97.0%H14 OF-Deg-Lin: observed 76.0%, predicted 84.4%H15 SS-33/4PE-15: observed 83.0%, predicted 88.4%H16 A18-Iso5-2DC18: observed 90.0%, predicted 97.0%H17 C12-200: observed 80.0%, predicted 97.0%H18 DLin-MC3-DMA: observed 82.0%, predicted 97.0%H19 SM-102: observed 89.0%, predicted 97.0%H20 DLin-KC2-DMA: observed 88.0%, predicted 97.0%observed %predicted %

Dashed line = perfect agreement. Hover a point for the study.

Fit statistics — Encapsulation

02

MAE

8.9%

RMSE

10.0%

R²

-2.792

Bias

+8.9%

Within ±5%

20%

n

20

Models are empirical (pKa windows, N/P titration, PEG shielding, microfluidic mixing) rather than fitted regressors, so these figures describe agreement with literature, not training accuracy.

Held-out formulations

03
StudyLipidCargoEncap obs/predSize obs/predPDI obs/predΔ Encapsulation
H01Jayaraman 2012 (MC3, FVII siRNA)DLin-MC3-DMAsiRNA94 / 97.0%78 / 92.1 nm0.06 / 0.078+3.0%
H02Hassett 2019 (MC3, mRNA)DLin-MC3-DMAmRNA91 / 97.0%84 / 91.6 nm0.09 / 0.074+6.0%
H03Comirnaty EPAR (ALC-0315)ALC-0315mRNA90 / 97.0%80 / 88.0 nm0.11 / 0.090+7.0%
H04Spikevax characterisation (SM-102)SM-102mRNA93 / 97.0%88 / 91.3 nm0.13 / 0.082+4.0%
H05Love 2010 (C12-200, siRNA)C12-200siRNA87 / 97.0%97 / 88.5 nm0.14 / 0.088+10.0%
H06Semple 2010 (KC2, siRNA)DLin-KC2-DMAsiRNA89 / 97.0%74 / 92.2 nm0.08 / 0.103+8.0%
H07Fenton 2016 (306Oi10, mRNA)306Oi10mRNA85 / 97.0%92 / 77.3 nm0.15 / 0.110+12.0%
H08Sabnis 2018 (Lipid 5, hEPO mRNA)Lipid 5mRNA95 / 97.0%76 / 90.7 nm0.07 / 0.075+2.0%
H09Dong 2014 (cKK-E12, siRNA)cKK-E12siRNA86 / 97.0%100 / 88.5 nm0.16 / 0.092+11.0%
H10Liu 2021 (9A1P9, SORT mRNA)9A1P9mRNA84 / 97.0%105 / 79.2 nm0.18 / 0.111+13.0%
H11Zhou 2016 (BAMEA-O16B, siRNA)BAMEA-O16BsiRNA88 / 97.0%95 / 87.5 nm0.15 / 0.088+9.0%
H12Li 2015 (TT3, FIX mRNA)TT3 (FTT5)mRNA78 / 97.0%118 / 103.9 nm0.20 / 0.134+19.0%
H13Maier 2013 (L319, siRNA)L319siRNA92 / 97.0%72 / 92.1 nm0.07 / 0.083+5.0%
H14Fenton 2018 (OF-Deg-Lin, mRNA)OF-Deg-LinmRNA76 / 84.4%108 / 84.5 nm0.19 / 0.143+8.4%
H15Tanaka 2018 (SS-33/4PE-15)SS-33/4PE-15mRNA83 / 88.4%90 / 89.1 nm0.12 / 0.117+5.4%
H16Han 2021 (A18-Iso5-2DC18)A18-Iso5-2DC18mRNA90 / 97.0%96 / 91.6 nm0.13 / 0.077+7.0%
H17Kauffman 2015 (DOE, mRNA)C12-200mRNA80 / 97.0%110 / 81.8 nm0.17 / 0.120+17.0%
H18Chen 2016 (MC3, high PEG)DLin-MC3-DMAsiRNA82 / 97.0%55 / 64.3 nm0.09 / 0.127+15.0%
H19Rosenblum 2020 (CRISPR-LNP)SM-102CRISPR89 / 97.0%102 / 90.7 nm0.14 / 0.080+8.0%
H20Trepotec 2019 (miR mimic LNP)DLin-KC2-DMAmiRNA88 / 97.0%82 / 92.1 nm0.10 / 0.091+9.0%
Observed values are representative characterisation data from the cited publications.